AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

RXST · NASDAQ · Medical - Devices

RxSight

Sells adjustable cataract lenses, light-delivery devices, and related service for ophthalmology practices.

$7.07

After-hours close+0.01 (+0.17%)

At close$7.06(+6.73%)

Something off on this page? Send us feedback.

Profile

RxSight, Inc.RXSTHealth Care

Commercializes the RxSight Light Adjustable Lens system for cataract surgery, combining LAL/LAL+ lenses with the Light Delivery Device and accessories. Revenue is driven mainly by recurring lens use after practices adopt the LDD, with commercial efforts centered on cataract surgeons in the United States and newer international launches.

Commercializes the RxSight Light Adjustable Lens system, a premium cataract technology built around LAL/LAL+ intraocular lenses, the Light Delivery Device, and related accessories and service. The lens is adjusted after implantation using programmed ultraviolet light delivered by the LDD.

Sales are concentrated on cataract practices in the United States, supported by direct device sales, account managers, clinical specialists, field service engineers, and marketing staff. Recent expansion has added launches or regulatory approvals in selected Asia-Pacific markets.

The model depends on LDD adoption translating into recurring LAL procedure volume. Larger premium intraocular-lens companies remain competitors, while Alcon is also a non-exclusive future-product partner. RxSight handles development and manufacturing and receives royalties, and Alcon leads global commercialization. FDA approvals, surgeon workflow adoption, installed-base productivity, and collaboration execution shape the pace of growth.

Company facts

CEORon Kurtz

ListedJul 30, 2021

ExchangeNASDAQ

HeadquartersAliso Viejo, CA

CountryUnited States

Employees461

CIK0001111485

ISINUS78349D1072

Key statistics

Market cap$291.8M

EPS (ttm)−$1.13

P/E (ttm)−6.24

ROE-17.4%

P/B1.11

P/S2.29

Dividend yield—

Beta1.21vs XLV 0.81

Year to date −32.0% · Average volume (30d) 886.4K

Analysts

Price target, next 12 months$6.75−4.3%Median of 12 analysts · vs the Aug 28 close

ConsensusHold3 of 12 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $7.05

High$11.00+56.0%

Median$6.75−4.3%

Low$5.50−22.0%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 10, 2026	Stifel Nicolaus	Target		$9	$7
Jul 28, 2026	UBS	Target			$5.50
Jul 7, 2026	Jefferies	Target		$72	$6.50
May 7, 2026	Needham	Reiterate	Buy	$13	$11
Mar 9, 2026	Stifel Nicolaus	Target		$10	$9

Earnings

EPS

Estimate−$0.29

ReportedDue Nov 4, 2026

Revenue

Estimate$27.2M

ReportedDue Nov 4, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	−$0.33	−$0.29	+12.0%	$32.5M	$33.7M	+3.7%	−3.34%
May 6, 2026Q1 FY26	−$0.30	−$0.38	−27.1%	$29.8M	$30.9M	+3.8%	−14.45%
Feb 25, 2026Q4 FY25	−$0.33	−$0.22	+34.3%	$30.2M	$32.6M	+8.1%	−10.10%
Nov 5, 2025Q3 FY25	−$0.19	−$0.04	+78.9%	$32.6M	$30.3M	−6.9%	+3.24%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$37.9M	$33.6M	$30.3M	$32.6M	$30.9M	$33.7M
Gross profit	$28.3M	$25.2M	$24.2M	$25.3M	$23.5M	$25.9M
Operating income	−$10.7M	−$14.0M	−$12.2M	−$11.3M	−$17.8M	−$13.8M
Net income	−$8.2M	−$11.8M	−$9.8M	−$9.2M	−$15.9M	−$12.1M
Diluted EPS	−$0.20	−$0.29	−$0.24	−$0.22	−$0.38	−$0.29
Gross margin	74.8%	74.9%	79.9%	77.5%	76.1%	76.7%
Operating margin	-28.2%	-41.6%	-40.1%	-34.8%	-57.7%	-40.8%

Fiscal years (4-quarter sums)FY21 $22.6M · FY22 $49.0M · FY23 $97.5M · FY24 $150.0M · FY25 $134.5M

Revenue by product · Q2 FY26

Service Warranty Service Contracts And Accessories$1.4M · 51%

L D D$1.3M · 49%

Balance sheet, Jun 30, 2026Cash & short-term investments $208.8M · Total debt $10.6M · Total assets $352.7M · Shareholders' equity $263.3M

Dividends

No dividends on record.

Ownership

Institutions 92.26%38.19M sharesInsiders 2.46%1.02M sharesOther 5.28%2.18M shares

Shares outstanding 41.40M · Float 39.09M · 94.4% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock Portfolio Management LLC	2.98M	7.20%	13G	Jul 17, 2026
Point72 Asset Management, L.P.	2.49M	6.00%	13G	Aug 19, 2026
Millennium Management LLC	2.06M	4.97%	13F	May 15, 2026
Artisan Partners Asset Management Inc.	2.06M	5.00%	13G	May 13, 2026
Nomura Holdings Inc	2.00M	4.83%	13F	May 15, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.